PUBLISHER: BIS Research | PRODUCT CODE: 1074021
PUBLISHER: BIS Research | PRODUCT CODE: 1074021
Axial Spondyloarthritis Market - A Global and Country Analysis: Focus on Commercialized Therapies, Potential Pipeline Products, Indication, and Country - Analysis and Forecast, 2022-2032
“Global Axial Spondyloarthritis Market to Reach $7,937.8 Million by 2032.”
Industry & Technology Overview
Global Axial Spondyloarthritis Market: Industry Overview
The global axial spondyloarthritis market was estimated to be at $1,873.8 million in 2021, which is expected to grow with a CAGR of 13.44% and reach $7,937.8 million by 2032. The growth in the global axial spondyloarthritis market is expected to be driven by the introduction of novel products, the increasing awareness about the disease, and the rising research and development investments, among others.
Market Lifecycle Stage
The global axial spondyloarthritis market is well established. Biopharmaceutical companies are trying to match themselves with new technologies in the market to improve the overall system from drug discovery to drug commercialization. The companies operating in the global axial spondyloarthritis market are now focusing more on biologics and personalized therapy to enhance therapeutics and improve patient outcomes. Also, major players such as AbbVie Inc., Eli Lilly and Company, Novartis International AG, and Pfizer Inc. are investing heavily in clinical trials for their respective therapeutic candidates to treat axial spondyloarthritis. Increasing investments in the research and development of drug manufacturing is one of the major opportunities in the global axial spondyloarthritis market.
Impact
With an increased worldwide focus on treating axial spondyloarthritis, the major market players are developing novel therapeutics, such as anti-janus kinase therapy, anti-interleukin therapy, and anti-tumor necrosis factor therapy, which is significantly impacting the growth of axial spondyloarthritis market. Due to the introduction of tumor necrosis factor inhibitors and interleukin 17 inhibitors, a new era of drug therapy was initiated for previously largely incurable diseases. For instance, the U.S. Food and Drug Administration approved three novel products, i.e., Xeljanz, Taltz, and Cosentyx, in 2020 and 2021 to treat patients with axial spondyloarthritis.
Drug development is more prominent in countries such as the U.S., Germany, and the U.K. Moreover, the presence of major market players such as UCB S.A., Johnson & Johnson Services, Inc., Merck & Co., Inc., Pfizer, Inc., Eli Lilly and Company, and Novartis International AG in seven major countries, including the U.S., EU4 (Germany, France, Spain, Italy) and U.K., and Japan have a positive impact on the market growth.
Impact of COVID-19
The COVID-19 pandemic has exerted tremendous strain on the research and clinical development of axial spondyloarthritis emerging therapies. Companies operating in axial spondyloarthritis have changed their focus on the research and development of drugs used for COVID-19 treatment to help governments and communities establish a new normal across the globe. This has resulted in the delayed launch of emerging therapies due to a shift in priorities regarding the COVID-19 pandemic. In addition, pharmaceutical companies are diverting their financial resources to develop and repurpose existing drug molecules to prevent and treat COVID-19. Most pharmaceutical companies have adopted this strategy to generate high revenue from the sale of COVID-19 drugs. These factors exert a combinatorial effect on the development and launch of emerging therapies intended to treat axial spondyloarthritis, such as ankylosing spondylitis and non-radiographic axial spondyloarthritis.
The production and supply associated with axial spondyloarthritis therapies have been massively disrupted due to the spread of COVID-19. Due to the pandemic, governments across the globe enforced lockdowns which significantly hampered commercial operations due to the ban imposed on transportation. This situation was majorly witnessed until the second quarter (Q2) of 2020, which negatively impacted the global axial spondyloarthritis market, resulting in a decline in revenue generated from therapy commercialization. Also, these instances resulted in limited access to emerging therapies used to treat axial spondyloarthritis.
In addition, the clinical trials have slowed down since the COVID-19 outbreak. The primary reason has been the difficulty in patient recruitment for the ongoing clinical trials, which will impact the launch timelines of the drugs. Most healthcare conferences were canceled, and most marketing activities transitioned to virtual methods. Moreover, organizations, such as CDC and ASCO, have indicated to refrain from clinical visits to patients.
However, with the ease of restrictions after the second quarter of 2020 coupled with the commencement of transportation activities, the market for axial spondyloarthritis has gained significant momentum and is anticipated to grow during the forecast period 2022-2032.
Market Segmentation
Axial Spondyloarthritis Market
Segmentation 1: by Commercialized Therapies
- Anti-Tumor Necrosis Factor (TNF) Therapy
- Anti-Interleukin (IL) Therapy
- Anti-Janus Kinase (JAK) Therapy
In 2021, the global axial spondyloarthritis market in the commercialized therapies segment was dominated by the anti-tumor necrosis factor therapy segment. Years of successive and significant innovations in anti-tumor necrosis factor therapies have demonstrated tremendous potential in treating distinct indications of axial spondyloarthritis.
Segmentation 2: by Potential Pipeline Products
- Anti-Janus Kinase (JAK) Therapy
- Anti-Interleukin (IL)-17 Therapy
- Other Therapy
In 2032, the global axial spondyloarthritis market is estimated to be dominated by the anti-interleukin 17 therapy and is expected to hold a 39.49% share of total potential pipeline products. Other therapy includes anti-Granulocyte/macrophage colony stimulating factor (GM-CSF) therapy and anti-phosphodiesterase 4 (PDE4) therapy.
Segmentation 3: by Indication
- Ankylosing Spondylitis
- Non-Radiographic Axial Spondyloarthritis
The ankylosing spondyloarthritis segment dominated the global axial spondyloarthritis market in 2021 due to a greater number of product approvals in seven major countries compared to non-radiographic axial spondyloarthritis.
Segmentation 4: by Country
- U.S.
- Germany
- France
- U.K.
- Italy
- Spain
- Japan
The U.S. axial spondyloarthritis market was valued at $1,231.2 million in 2021 and is the leading market contributor. The growth can be attributed to the increased research and development activities in the country.
Recent Developments in the Global Axial Spondyloarthritis Market
- In December 2020, AbbVie's Upadacitinib (RINVOQ) met primary as well as secondary endpoints in the Phase III study for non-radiographic axial spondyloarthritis. * In August 2020, AbbVie, Inc. submitted an application to the U.S. Food and Drug Administration (FDA) to seek approval for RINVOQ (Upadacitinib) to treat adult patients with active ankylosing spondylitis.
- In March 2020, Novartis International AG received a positive CHMP opinion which recommended a positive opinion for Cosentyx for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA).
- In June 20219, Kyowa Hakko Kirin Co., Ltd. stated a positive result of a 16-week efficacy and safety analysis of the Phase 3 study of Brodalumab in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis.
Demand - Drivers and Limitations
Following are the demand drivers for the global axial spondyloarthritis market:
- The Introduction of Novel Products
- Increasing Awareness About the Disease
- Rising Research and Development Investments
The market is expected to face some limitations too due to the following challenges:
- High Treatment Cost Impacting the Adoption Rate
- Increased Delay in Diagnosis
How Can This Report Add Value to an Organization?
- Product/Innovation Strategy: The product segment helps the reader understand the commercialized therapies present in the market, along with potential pipeline products that are in different stages of clinical trials. Moreover, the study provides the reader with a detailed understanding of two different indications such as ankylosing spondyloarthritis and non-radiographic axial spondyloarthritis.
- Growth/Marketing Strategy: The global axial spondyloarthritis market has seen major development by key players operating in the market, such as regulatory and legal activities, product approvals, partnerships and alliances, and merger and acquisition activities. The favored strategy for the companies has been regulatory and legal activities along with product approvals to strengthen their position in the market. For instance, in December 2021, Pfizer Inc. received approval for Xeljanz/Xeljanz XR (tofacitinib) by the U.S. Food and Drug Administration to treat adults dealing with active ankylosing spondylitis (AS).
- Competitive Strategy: Key players in the global axial spondyloarthritis market analyzed and profiled in the study involve axial spondyloarthritis-based drug manufacturers. Moreover, a detailed competitive benchmarking of players operating in the global axial spondyloarthritis market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.
Total Number of Companies Profiled: 12.
Public companies include: AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Johnson & Johnson Services, Inc., Kyowa Kirin Co., Ltd., Merck & Co., Inc., Novartis International AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, and UCB S.A. The private company profiled is FunPep Co., Ltd.
Table of Contents
1 Market
- 1.1 Product Definition
- 1.1.1 Radiographic Axial Spondyloarthritis
- 1.1.2 Non-radiographic Axial Spondyloarthritis (nr-axSpA):
- 1.1.3 Inclusion and Exclusion
- 1.2 Market Scope
- 1.2.1 Key Questions Answered in the Report
- 1.3 Research Methodology
- 1.3.1 Global Axial Spondyloarthritis Market: Research Methodology
- 1.3.2 Data Sources
- 1.3.2.1 Primary Data Sources
- 1.3.2.2 Secondary Data Sources
- 1.3.3 Market Estimation Model
- 1.3.4 Criteria for Company Profiling
- 1.4 Market Overview
- 1.4.1 Introduction
- 1.4.2 Current Market Size and Growth Potential, $Million, 2021-2032
- 1.4.3 Disease Background
- 1.4.4 Treatment Plan
- 1.4.4.1 Tumor Necrosis Factor (TNF) Inhibitors
- 1.4.4.2 Interleukin (IL)-17 Inhibitors
- 1.4.4.3 Janus Kinase (JAK) Inhibitors
- 1.4.5 Treatment Guidelines for Axial Spondyloarthritis
- 1.4.5.1 American College of Rheumatology (ACR) Recommendations
- 1.4.5.2 Assessment of SpondyloArthritis international Society (ASAS) and European League Against Rheumatism (EULAR) Recommendations
- 1.4.6 Epidemiology of Axial Spondyloarthritis
- 1.4.6.1 U.S. Epidemiology of Axial Spondyloarthritis
- 1.4.6.2 Epidemiology of Axial Spondyloarthritis (Germany, France, Italy, and Spain (EU4) + U.K.)
- 1.4.6.3 Japan Epidemiology of Axial Spondyloarthritis
- 1.4.7 Pipeline Analysis
- 1.4.7.1 By Clinical Phase
- 1.4.8 Impact of COVID-19 on Global Axial Spondyloarthritis Market
- 1.4.8.1 Interruption in Research and Clinical Development and Commercial Operation
- 1.4.8.1.1 Research and Clinical Development
- 1.4.8.1.2 Commercial Operation and Access
- 1.4.8.2 Navigating Crisis Recovery and Looking to the Future
- 1.4.8.1 Interruption in Research and Clinical Development and Commercial Operation
2 Industry Analysis
- 2.1 Overview
- 2.2 Legal Requirements and Frameworks in the U.S.
- 2.2.1 Clinical Trial Authorization
- 2.2.2 Marketing Authorization
- 2.2.3 U.S. Food and Drug Administration Guidelines for Biologics License Application (BLA)
- 2.2.4 Post-Authorization Regulations
- 2.3 Legal Requirements and Frameworks in Europe
- 2.4 Legal Requirements and Frameworks in Japan
- 2.5 Reimbursement and Cost Analysis
- 2.5.1 U.S.
- 2.5.2 Europe
3 Market Dynamics
- 3.1 Overview
- 3.2 Impact Analysis
- 3.3 Market Drivers
- 3.3.1 The Introduction of Novel Products
- 3.3.2 Increasing Awareness About the Disease
- 3.3.3 Rising Research and Development Investments
- 3.4 Market Restraints
- 3.4.1 High Treatment Cost Impacting the Adoption Rate
- 3.4.2 Increased Delay in Diagnosis
- 3.5 Market Opportunities
- 3.5.1 Massive Scope in Emerging Markets
4 Competitive Landscape
- 4.1 Overview
- 4.2 Key Developments and Strategies
- 4.2.1 Regulatory and Legal Activities
- 4.2.2 Product Approvals
- 4.2.3 Partnerships and Alliances
- 4.2.4 Merger and Acquisition Activities
- 4.3 Market Share Analysis, by Company (2021)
- 4.4 Growth Share Analysis
5 Global Axial Spondyloarthritis Market (by Commercialized Therapies), $Million, 2021-2032
- 5.1 Overview
- 5.2 Anti-Tumor Necrosis Factor (TNF) Therapy
- 5.2.1 Cimzia (Certolizumab Pegol)
- 5.2.1.1 Cimzia for Indication 1 (Ankylosing Spondylitis)
- 5.2.1.2 Cimzia for Indication 2 (Non-radiographic Axial Spondyloarthritis)
- 5.2.2 Simponi (Golimumab)
- 5.2.2.1 Simponi for Indication 1 (Ankylosing Spondylitis)
- 5.2.2.1.1 Simponi as Subcutaneous Formulation
- 5.2.2.1.2 Simponi AREA as an Intravenous Formulation
- 5.2.2.2 Simponi for Indication 2 (Non-radiographic Axial Spondyloarthritis)
- 5.2.2.1 Simponi for Indication 1 (Ankylosing Spondylitis)
- 5.2.1 Cimzia (Certolizumab Pegol)
- 5.3 Anti-Interleukin (IL) Therapy
- 5.3.1 Cosentyx (Secukinumab)
- 5.3.1.1 Cosentyx for Indication 1 (Ankylosing Spondylitis)
- 5.3.1.2 Cosentyx for Indication 2 (Non-radiographic Axial Spondyloarthritis)
- 5.3.2 Taltz (Ixekizumab)
- 5.3.2.1 Taltz for Indication 1 (Ankylosing Spondylitis)
- 5.3.2.2 Taltz for Indication 2 (Non-radiographic Axial Spondyloarthritis)
- 5.3.3 Lumicef (Brodalumab/KHK4827)
- 5.3.3.1 Lumicef for Indication 1 (Ankylosing Spondylitis)
- 5.3.3.2 Lumicef for Indication 2 (Non-radiographic Axial Spondyloarthritis)
- 5.3.1 Cosentyx (Secukinumab)
- 5.4 Anti-Janus Kinase (JAK) Therapy
- 5.4.1 Xeljanz/Xeljanz XR (Tofacitinib)
6 Global Axial Spondyloarthritis Market (by Potential Pipeline Products), $Million, 2021-2032
- 6.1 Overview
- 6.2 Anti-Janus Kinase (JAK) Therapy
- 6.2.1 Rinvoq (Upadacitinib)
- 6.2.2 SHR0302
- 6.3 Anti-Interleukin (IL)-17 Therapy
- 6.3.1 Bimzelx (Bimekizumab)
- 6.3.1.1 Bimzelx for Indication 1 (Ankylosing Spondylitis)
- 6.3.1.2 Bimzelx for Indication 2 (Non-radiographic Axial Spondyloarthritis)
- 6.3.1 Bimzelx (Bimekizumab)
- 6.4 Other Therapy
- 6.4.1 IZN-101 (Namilumab)
- 6.4.2 Otezla (Apremilast)
7 Global Axial Spondyloarthritis Market (by Indication), $Million, 2021-2032
- 7.1 Overview
- 7.1.1 Ankylosing Spondylitis
- 7.1.2 Non-radiographic Axial Spondyloarthritis
8 Global Axial Spondyloarthritis Market (by Country), $Million, 2021-2032
- 8.1 Overview
- 8.1.1 Commercialized Products in the U.S.
- 8.1.2 Commercialized Products in EU4 + U.K.
- 8.1.3 Commercialized Products in Japan
- 8.2 U.S.
- 8.3 Germany
- 8.4 France
- 8.5 U.K.
- 8.6 Italy
- 8.7 Spain
- 8.8 Japan
9 Company Profiles
- 9.1 Overview
- 9.2 AbbVie Inc.
- 9.2.1 Company Overview
- 9.2.2 Role of AbbVie Inc. in the Global Axial Spondyloarthritis Market
- 9.2.3 Financials
- 9.2.4 Key Insights About Financial Health of the Company
- 9.2.5 SWOT Analysis
- 9.3 Amgen Inc.
- 9.3.1 Company Overview
- 9.3.2 Role of Amgen Inc. in the Global Axial Spondyloarthritis Market
- 9.3.3 Financials
- 9.3.4 Key Insights About Financial Health of the Company
- 9.3.5 SWOT Analysis
- 9.4 Bristol-Myers Squibb Company
- 9.4.1 Company Overview
- 9.4.2 Role of Bristol-Myers Squibb Company in the Global Axial Spondyloarthritis Market
- 9.4.3 Financials
- 9.4.4 Key Insights About Financial Health of the Company
- 9.4.5 SWOT Analysis
- 9.5 Eli Lilly and Company
- 9.5.1 Company Overview
- 9.5.2 Role of Eli Lilly and Company in the Global Axial Spondyloarthritis Market
- 9.5.3 Financials
- 9.5.4 Key Insights About Financial Health of the Company
- 9.5.5 SWOT Analysis
- 9.6 FunPep Co., Ltd.,
- 9.6.1 Company Overview
- 9.6.2 Role of FunPep Co., Ltd., in the Global Axial Spondyloarthritis Market
- 9.6.3 SWOT Analysis
- 9.7 Johnson & Johnson Services, Inc.
- 9.7.1 Company Overview
- 9.7.2 Role of Johnson & Johnson Services, Inc. in the Global Axial Spondyloarthritis Market
- 9.7.3 Financials
- 9.7.4 Key Insights About Financial Health of the Company
- 9.7.5 SWOT Analysis
- 9.8 Kyowa Kirin Co., Ltd.
- 9.8.1 Company Overview
- 9.8.2 Role of Kyowa Kirin Co., Ltd. in the Global Axial Spondyloarthritis Market
- 9.8.3 Financials
- 9.8.4 Key Insights About Financial Health of the Company
- 9.8.5 SWOT Analysis
- 9.9 Merck & Co., Inc.
- 9.9.1 Company Overview
- 9.9.2 Role of Merck & Co., Inc. in the Global Axial Spondyloarthritis Market
- 9.9.3 Financials
- 9.9.4 Key Insights About Financial Health of the Company
- 9.9.5 SWOT Analysis
- 9.1 Novartis International AG
- 9.10.1 Company Overview
- 9.10.2 Role of Novartis International AG in the Global Axial Spondyloarthritis Market
- 9.10.3 Financials
- 9.10.4 Key Insights About Financial Health of the Company
- 9.10.5 SWOT Analysis
- 9.11 Pfizer Inc.
- 9.11.1 Company Overview
- 9.11.2 Role of Pfizer Inc. in the Global Axial Spondyloarthritis Market
- 9.11.3 Financials
- 9.11.4 Key Insights About Financial Health of the Company
- 9.11.5 SWOT Analysis
- 9.12 Takeda Pharmaceutical Company Limited
- 9.12.1 Company Overview
- 9.12.2 Role of Takeda Pharmaceutical Company Limited in the Global Axial Spondyloarthritis Market
- 9.12.3 Financials
- 9.12.4 Key Insights About Financial Health of the Company
- 9.12.5 SWOT Analysis
- 9.13 UCB S.A.
- 9.13.1 Company Overview
- 9.13.2 Role of UCB S.A. in the Global Axial Spondyloarthritis Market
- 9.13.3 Financials
- 9.13.4 Key Insights About Financial Health of the Company
- 9.13.5 SWOT Analysis
List of Figures
- Figure 1: Axial Spondyloarthritis Drugs Approved by U.S. FDA (2015-2021)
- Figure 2: Axial Spondyloarthritis Drugs Global Clinical Trials (by Phase)
- Figure 3: Global Axial Spondyloarthritis Market (by Commercialized Therapies), $Million, 2021-2032
- Figure 4: Global Axial Spondyloarthritis Market: Impact Analysis
- Figure 5: Global Axial Spondyloarthritis Market (by Potential Pipeline Products), $Million, 2021-2032
- Figure 6: Global Axial Spondyloarthritis Market (by Indication), $Million, 2021-2032
- Figure 7: Global Axial Spondyloarthritis Market (by Country), $Million, 2021-2032
- Figure 8: Global Axial Spondyloarthritis Market: Segmentation
- Figure 9: Global Axial Spondyloarthritis Market: Methodology
- Figure 10: Primary Research Methodology
- Figure 11: Bottom-Up Approach (Segment-Wise Analysis)
- Figure 12: Step by Step Approach
- Figure 13: Global Axial Spondyloarthritis Market, $Million, 2021-2032
- Figure 14: Evolution of Axial Spondyloarthritis (axSpA)
- Figure 15: Treatment Plan for Axial Spondyloarthritis
- Figure 16: Complications with Tumor Necrosis Factor (TNF) Inhibitors
- Figure 17: Complications with Interleukin (IL)-17 Inhibitors
- Figure 18: Complications with Janus Kinase (JAK) Inhibitors
- Figure 19: Treatment Guidelines for Axial Spondyloarthritis, U.S.
- Figure 20: Assessment of Spondyloarthritis International Society (ASAS) and The European League Against Rheumatism (EULAR) Recommendations for the Management of Axial Spondyloarthritis (axSpA)
- Figure 21: Assessment of Spondyloarthritis International Society (ASAS) and The European League Against Rheumatism (EULAR) 13 Recommendations
- Figure 22: Types of Axial Spondyloarthritis
- Figure 23: Axial Spondyloarthritis Prevalence (U.S. + EU4 + U.K. + Japan), 2020-2032
- Figure 24: Axial Spondyloarthritis Prevalence in the U.S., 2020-2032
- Figure 25: Percentage of Axial Spondyloarthritis Prevalence (by Country), 2020
- Figure 26: Axial Spondyloarthritis Prevalence in the EU4 + U.K., 2020-2032
- Figure 27: Axial Spondyloarthritis Prevalence in Japan, 2020-2032
- Figure 28: Axial Spondyloarthritis Emerging Therapies: Developmental Phases
- Figure 29: Key Steps to Navigate Crisis Recovery
- Figure 30: Clinical Trial Authorization for Axial Spondyloarthritis Therapeutics
- Figure 31: Process for Obtaining Marketing Authorization
- Figure 32: U.S. Food and Drug Administration Review Timeline
- Figure 33: EMA Review Timeline
- Figure 34: Current Reimbursement Scenario in Europe
- Figure 35: Number of Clinical Trials for Axial Spondyloarthritis (by Major Players)
- Figure 36: Factors Responsible for Delayed Diagnosis in Axial Spondyloarthritis
- Figure 37: Share of Key Developments and Strategies, January 2019-February 2022
- Figure 38: Regulatory and Legal Activities (by Company), January 2019 to February
- Figure 39: Product Approvals (by Company), January 2019 and February 2022
- Figure 40: Partnerships and Alliances (by Company), January 2019 and February 2022
- Figure 41: Merger and Acquisition Activities (by Company), January 2019 and February 2022
- Figure 42: Market Share Analysis (by Company), 2021
- Figure 43: Growth Share Matrix for Global Axial Spondyloarthritis Market (by Company), 2021
- Figure 44: Global Axial Spondyloarthritis Market (by Commercialized Therapies), $Million, 2021-2032
- Figure 45: Global Axial Spondyloarthritis Market (by Anti-Tumor Necrosis Factor (TNF) Therapy), $Million, 2021-2032
- Figure 46: Global Revenue for Cimzia, $Million, 2021-2032
- Figure 47: Global Revenue for Cimzia (Ankylosing Spondylitis), $Million, 2021-2032
- Figure 48: Global Revenue for Cimzia (Non-radiographic Axial Spondyloarthritis), $Million, 2021-2032
- Figure 49: Global Revenue for Simponi, $Million, 2021-2032
- Figure 50: Global Revenue for Simponi (Ankylosing Spondylitis), $Million, 2021-2032
- Figure 51: Global Revenue for Simponi AREA (Ankylosing Spondylitis), $Million, 2021-2032
- Figure 52: Global Revenue for Simponi (Non-radiographic Axial Spondyloarthritis), $Million, 2021-2032
- Figure 53: Global Axial Spondyloarthritis Market (by Anti-Interleukin (IL) Therapy), $Million, 2021-2032
- Figure 54: Global Revenue for Cosentyx, $Million, 2021-2032
- Figure 55: Global Revenue for Cosentyx (Ankylosing Spondylitis), $Million, 2021-2032
- Figure 56: Global Revenue for Cosentyx (Non-radiographic Axial Spondyloarthritis), $Million, 2021-2032
- Figure 57: Global Revenue for Taltz, $Million, 2021-2032
- Figure 58: Global Revenue for Taltz (Ankylosing Spondylitis), $Million, 2021-2032
- Figure 59: Global Revenue for Taltz (Non-radiographic Axial Spondyloarthritis), $Million, 2021-2032
- Figure 60: Global Revenue for Lumicef, $Million, 2021-2032
- Figure 61: Global Revenue for Lumicef (Ankylosing Spondylitis), $Million, 2021-2032
- Figure 62: Global Revenue for Lumicef (Non-radiographic Axial Spondyloarthritis), $Million, 2021-2032
- Figure 63: Global Revenue for Xeljanz/Xeljanz XR, $Million, 2021-2032
- Figure 64: Global Axial Spondyloarthritis Market (by Potential Pipeline Products), $Million, 2021-2032
- Figure 65: Global Axial Spondyloarthritis Market (by Potential Pipeline Products), by Anti-Janus Kinase Therapy), $Million, 2021-2032
- Figure 66: Global Revenue for Rinvoq, $Million, 2021-2032
- Figure 67: Upadaticinib Phase III Clinical Trial Design for Non-radiographic Axial Spondyloarthritis
- Figure 68: Global Revenue for SHR0302, $Million, 2021-2032
- Figure 69: SHR0302 Phase II/ Phase III Clinical Trial Design for Ankylosing Spondylitis
- Figure 70: Global Revenue for Bimzelx, $Million, 2021-2032
- Figure 71: Global Revenue for Bimzelx (Ankylosing Spondylitis), $Million, 2021-2032
- Figure 72: Bimzelx Phase III Clinical Trial Design for Ankylosing Spondylitis
- Figure 73: Global Revenue for Bimzelx (Non-radiographic Axial Spondyloarthritis), $Million, 2021-2032
- Figure 74: Bimzelx Phase III Clinical Trial Design for Non-radiographic Axial Spondyloarthritis
- Figure 75: Global Axial Spondyloarthritis Market (by Potential Pipeline Products), by Other Therapy), $Million, 2021-2032
- Figure 76: Global Revenue for IZN-101, $Million, 2021-2032
- Figure 77: IZN-101 Phase II Clinical Trial Design for Axial Spondyloarthritis
- Figure 78: Global Revenue for Otezla, $Million, 2021-2032
- Figure 79: Otezla Phase III Clinical Trial Design for Ankylosing Spondylitis
- Figure 80: Global Axial Spondyloarthritis Market (by Indication), $Million, 2021-2032
- Figure 81: Global Axial Spondyloarthritis Market (by Indication, by Ankylosing Spondylitis), $Million, 2021-2032
- Figure 82: Global Axial Spondyloarthritis Market (by Indication, by Non-Radiographic Axial Spondyloarthritis), $Million, 2021-2032
- Figure 83: Global Axial Spondyloarthritis Market (by Country), $Million, 2021-2032
- Figure 84: U.S. Axial Spondyloarthritis Market, $Million, 2021-2032
- Figure 85: Germany Axial Spondyloarthritis Market, $Million, 2021-2032
- Figure 86: France Axial Spondyloarthritis Market, $Million, 2021-2032
- Figure 87: U.K. Axial Spondyloarthritis Market, $Million, 2021-2032
- Figure 88: Italy Axial Spondyloarthritis Market, $Million, 2021-2032
- Figure 89: Spain Axial Spondyloarthritis Market, $Million, 2021-2032
- Figure 90: Japan Axial Spondyloarthritis Market, $Million, 2021-2032
- Figure 91: Total Number of Companies Profiled
- Figure 92: AbbVie Inc.: Pre-Clinical and Clinical Assets
- Figure 93: AbbVie Inc.: Overall Financials, $Million, 2019-2021
- Figure 94: AbbVie, Inc.: Revenue (by Region), $Million, 2019-2021
- Figure 95: AbbVie Inc.: R&D Expenditure, $Million, 2019-2021
- Figure 96: AbbVie Inc.: SWOT Analysis
- Figure 97: Amgen Inc.: Pre-Clinical and Clinical Assets
- Figure 98: Amgen Inc.: Overall Financials, $Million, 2019-2021
- Figure 99: Amgen Inc.: Revenue (by Region), $Million, 2019-2021
- Figure 100: Amgen Inc.: R&D Expenditure, $Million, 2019-2021
- Figure 101: Amgen Inc.: SWOT Analysis
- Figure 102: Bristol-Myers Squibb Company: Pre-Clinical and Clinical Assets
- Figure 103: Bristol-Myers Squibb Company: Overall Financials, $Million, 2019-2021
- Figure 104: Bristol-Myers Squibb Company: Revenue (by Region), $Million, 2019-2021
- Figure 105: Bristol-Myers Squibb Company: R&D Expenditure, $Million, 2019-2021
- Figure 106: Bristol-Myers Squibb Company: SWOT Analysis
- Figure 107: Eli Lilly and Company: Commercialized Therapy
- Figure 108: Eli Lilly and Company: Overall Financials, $Million, 2019-2021
- Figure 109: Eli Lilly and Company: Revenue (by Region), $Million, 2019-2021
- Figure 110: Eli Lilly and Company: R&D Expenditure, $Million, 2019-2021
- Figure 111: Eli Lilly and Company: SWOT Analysis
- Figure 112: FunPep Co., Ltd.: Pre-Clinical and Clinical Assets
- Figure 113: FunPep Co., Ltd.: SWOT Analysis
- Figure 114: Johnson & Johnson Services, Inc.: Commercialized Therapy
- Figure 115: Johnson & Johnson Services, Inc.: Overall Financials, $Million, 2019-2021
- Figure 116: Johnson & Johnson Services, Inc.: Revenue (by Segment), $Million, 2019-2021
- Figure 117: Johnson & Johnson Services, Inc.: Revenue (by Region), $Million, 2019-2021
- Figure 118: Johnson & Johnson Services, Inc.: R&D Expenditure, $Million, 2019-2021
- Figure 119: Johnson & Johnson Services, Inc.: SWOT Analysis
- Figure 120: Kyowa Kirin Co., Ltd. Commercialized Therapy
- Figure 121: Kyowa Kirin Co., Ltd. Overall Financials, $Million, 2019-2021
- Figure 122: Kyowa Kirin Co., Ltd. Revenue (by Region), $Million, 2019-2021
- Figure 123: Kyowa Kirin Co., Ltd. R&D Expenditure, $Million, 2019-2021
- Figure 124: Kyowa Kirin Co., Ltd. SWOT Analysis
- Figure 125: Merck & Co., Inc.: Commercialized Therapy
- Figure 126: Merck & Co., Inc.: Overall Financials, $Million, 2019-2021
- Figure 127: Merck & Co., Inc.: Revenue (by Segment), $Million, 2019-2021
- Figure 128: Merck & Co., Inc.: Revenue (by Region), $Million, 2019-2021
- Figure 129: Merck & Co., Inc.: R&D Expenditure, $Million, 2019-2021
- Figure 130: Merck & Co., Inc.: SWOT Analysis
- Figure 131: Novartis International AG: Commercialized Therapy
- Figure 132: Novartis International AG: Overall Financials, $Million, 2019-2021
- Figure 133: Novartis International AG: Revenue (by Segment), $Million, 2019-2021
- Figure 134: Novartis International AG: Revenue (by Region), $Million, 2019-2021
- Figure 135: Novartis International AG: R&D Expenditure, $Million, 2019-2021
- Figure 136: Novartis International AG: SWOT Analysis
- Figure 137: Pfizer Inc.: Commercialized Therapy
- Figure 138: Pfizer Inc.: Overall Financials, $Million, 2019-2021
- Figure 139: Pfizer Inc.: Revenue (by Region), $Million, 2019-2021
- Figure 140: Pfizer Inc.: R&D Expenditure, $Million, 2019-2021
- Figure 141: Pfizer Inc.: SWOT Analysis
- Figure 142: Takeda Pharmaceutical Company Limited: Pre-Clinical and Clinical Assets
- Figure 143: Takeda Pharmaceutical Company Limited: Overall Financials, $Million, 2018-2020
- Figure 144: Takeda Pharmaceutical Company Limited: Revenue (by Region), $Million, 2018-2020
- Figure 145: Takeda Pharmaceutical Company Limited: R&D Expenditure, $Million, 2018-2020
- Figure 146: Takeda Pharmaceutical Company Limited: SWOT Analysis
- Figure 147: UCB S.A.: Commercialized Therapy
- Figure 148: UCB S.A.: Pre-Clinical and Clinical Assets
- Figure 149: UCB S.A.: Overall Financials, $Million, 2019-2021
- Figure 150: UCB S.A.: Revenue (by Region), $Million, 2019-2021
- Figure 151: UCB S.A.: R&D Expenditure, $Million, 2019-2021
- Figure 152: UCB S.A.: SWOT Analysis
List of Tables
- Table 1: Annual Cost of Approved Axial Spondyloarthritis Therapeutics in U.S.
- Table 2: Likert Scale
- Table 3: Impact Analysis of Market Drivers
- Table 4: Impact Analysis of Market Restraints
- Table 5: Approved Biologic Agents for Axial Spondyloarthritis (axSpA), (2020-2021)
- Table 6: Approved Axial Spondyloarthritis Products in Developed Nations
- Table 7: Axial Spondyloarthritis Drugs for Ankylosing Spondylitis
- Table 8: Axial Spondyloarthritis Drugs for Non-radiographic Axial Spondyloarthritis
- Table 9: List of Selective Axial Spondyloarthritis Commercialized Products in the U.S.
- Table 10: List of Selective Axial Spondyloarthritis Commercialized Products in the EU4 + U.K.
- Table 11: List of Selective Axial Spondyloarthritis Commercialized Products in Japan
- Table 12: Taltz (Ixekizumab): Indications
- Table 13: Simponi/Simponi Area (Golimumab): Indications
- Table 14: Lumicef (Brodalumab/KHK4827): Indications
- Table 15: Simponi (Golimumab): Indications
- Table 16: Cosentyx (Secukinumab): Indications
- Table 17: Xeljanz/Xeljanz XR: Indications
- Table 18: Cimzia (Certolizumab Pegol): Indications
